Publications

  1. Sievers Q, Lu H, Cool A, Gajewski S, Kong T, Noviski MA, Whelan S, Wang Y, Mendoza Navarrete L, Mi X, Ficici E, Mukerji R, Iuliano JN, Ye J, Sanchez Garcia De Los Rios M, Bousquet H, Tan M, Brathaban N, Narasappa N, Lu YW, Elechko J, Maron MI, Phelps CB, Rahman J, Notti RQ, Sekeres S, Lamkin EN, Bravo E, Alencar A, Ewalt MD, Islam P, Mato AR, Roeker L, Bhatt S, Taylor J, Thompson MC, Hansen GM, Abdel-Wahab O. Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors. Cancer Discov. 2026 Jul 22 Epub 2026 July 22
    View PubMed
  2. Davids MS, Eyre TA, Woyach JA, Roeker LE, Ferrajoli A, Wang Y, Tam CS, Jurczak W, Zinzani PL, Simkovic M, Li JY, Bosch F, Roos-Weil D, Cramer P, Osterborg A, Islam P, Jacobs R, Skarbnik A, Bhat SA, Kang S, Chen M, Nguyen B, McNeely SC, Chung KL, Oliveira JM, Ito R, Ghia P, Wierda WG. Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet. 2026 Jul 9 Epub 2026 July 09
    View PubMed
  3. Parikh SA, Hampel PJ, Roeker LE, Wang Y, Tsang M, Parrondo R, Bailen R, Koehler A, Behnken AL, Wagner CC, Hilal T, Ailawadhi S, Munoz JL, Rosenthal AC, Chanan-Khan A, Zepeda-Mendoza CJ, King RL, Hanson CA, Braggio E, Slager SL, Call TG, Leis JF, Shi M, Kenderian SS, Kay NE. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Mayo Clinic Systematic Management and Risk-Adapted Therapy for Lymphoid Malignancies (lySMART) Consensus Guidelines 2026. Mayo Clin Proc. 2026 Jul; 101 (7):1185-1201 Epub 2026 June 05
    View PubMed
  4. Roeker L, Thompson MC. Can minimal residual disease be used to tailor therapy duration for chronic lymphocytic leukemia patients? Expert Rev Hematol. 2026 Apr; 19 (4):373-378 Epub 2026 Jan 26
    View PubMed
  5. Baccon D, Atallah-Yunes SA, Hampel PJ, Roeker LE, Kenderian SS, Muchtar E, Kay NE, Koehler AB, Behnken AL, Wagner CC, Johnston PB, Nowakowski GS, Habermann TM, Hilal T, Tsang M, Leis JF, Rosenthal AC, Parrondo RD, Tun HW, Shi M, King RL, He R, Parikh SA, Wang Y. Central nervous system involvement in patients with Richter transformation of chronic lymphocytic leukemia (CLL): the Mayo Clinic experience. Blood Cancer J 2026 Jan 7; 16 (1):7 Epub 2026 Jan 07
    View PubMed
  6. Brown JR, Nguyen B, Desikan SP, Won H, Tantawy SI, McNeely SC, Marella N, Randeria HS, Hanson LM, Parker A, Calado Botelho S, Woyach JA, Patel K, Tam CS, Eyre TA, Cheah CY, Shah NN, Ghia P, Jurczak W, Balbas M, Nair BC, Abada PB, Wang C, Wang D, Roeker LE, Gandhi V, Wierda WG. Genomic Determinants of Response and Resistance to Pirtobrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood. 2025 Oct 7 Epub 2025 Oct 07
    View PubMed
  7. Miller CR, Huang Y, Allan JN, Bhat SA, Bond D, Brander D, Byrd JC, Chavez J, Chong E, Danilov A, Dowling MR, Dvorak-Kornaus K, Hampel PJ, Ho C, Islam P, Malakhov N, Matasar M, Miller S, Parikh SA, Rabe KG, Rhodes JM, Roeker LE, Rogers KA, Saha A, Skarbnik A, Scott H, Schade J, Shadman M, Shouse G, Sojitra P, Stephens DM, Thompson MC, Thompson PA, Wang Y, Woyach JA, Yano M, Omer Z, Kittai AS. Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era. Am J Hematol 2025 Sep; 100 (9):1709-1713 Epub 2025 July 02
    View PubMed
  8. Kosydar S, Archibald WJ, Hampel PJ, Call TG, Achenbach SJ, Rabe KG, Hanson CA, Koehler AB, Muchtar E, Kenderian SS, Leis JF, Wang Y, Roeker LE, Hilal T, Tsang M, Parrondo RD, Braggio E, Shi M, Schwager SM, Slager SL, Kay NE, Parikh SA. The role of imaging studies in predicting time to first treatment and overall survival in high-count monoclonal B-cell lymphocytosis. Br J Haematol. 2025 Sep; 207 (3):860-868 Epub 2025 July 15
    View PubMed
  9. Sharman JP, Munir T, Grosicki S, Roeker LE, Burke JM, Chen CI, Grzasko N, Follows G, Matrai Z, Sanna A, Qiu L, Feng R, Hua VM, Jurczak W, Ritgen M, Yi S, Bosch F, Coombs CC, Bao K, Patel V, Liu B, Compte L, Guntur A, Wang DY, Hill M, Leow CC, Ghia P, Barr PM. Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). J Clin Oncol. 2025 Aug; 43 (22):2538-2549 Epub 2025 June 06
    View PubMed
  10. Kwiatek M, Murthy GSG, Hoffmann M, Tessoulin B, Danilov A, Alencar AJ, Shah NN, Ghesquieres H, Le Gouill S, Jurczak W, Han H, Yuen E, Patel V, Guo-Avrutin Y, Pauff JM, Roeker LE. A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies. Clin Lymphoma Myeloma Leuk. 2025 Jul; 25 (7):512-519 Epub 2025 Jan 28
    View PubMed
  11. Roeker LE, Burke JM, Rhodes JM, Emechebe N, Jawaid D, Manzoor BS, Jensen CE, Ryland L, Liu Y, Marx SE, Sinai W, Roser J, Shadman M. Real-World Effectiveness of Frontline Treatments Among Patients with Chronic Lymphocytic Leukemia: Results from ConcertAI. Cancers (Basel). 2025 Feb 26; 17 (5)
    View PubMed
  12. Kittai AS, Huang Y, Miller S, Allan JN, Bhat SA, Bond DA, Brander DM, Byrd JC, Chavez JC, Chong E, Davids MS, Danilov AV, Ding W, Dowling MR, Dvorak-Kornaus K, Freedman H, Hampel PJ, Ho C, Hwang SR, Islam P, Malakhov N, Matasar M, Miller C, Omer Z, Parikh SA, Parry E, Rabe KG, Raess PW, Rai M, Roeker L, Rhodes J, Rogers KA, Saha A, Schade J, Scott HW, Shadman M, Shouse G, Skarbnik A, Spurgeon S, Stephens DM, Thompson MC, Thompson PA, Wang Y, Yano M, Woyach JA. Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL. Blood Cancer J 2025 Feb 20; 15 (1):23
    View PubMed
  13. Mitchell AP, Persaud S, Mishra Meza A, Fuchs HE, De P, Tabatabai S, Chakraborty N, Dey P, Trivedi NU, Mailankody S, Blinder V, Green A, Epstein AS, Daly B, Roeker L, Bach PB, Gonen M. Quality of Treatment Selection for Medicare Beneficiaries With Cancer. J Clin Oncol. 2025 Feb 10; 43 (5):524-535 Epub 2024 Oct 11
    View PubMed
  14. Chin KK, Derkach A, Famulare C, Gupta GK, Borge PD, Geyer MB, Goldberg AD, Haque T, Park JH, Roeker LE, Tallman MS, Stahl M, Stein EM. HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML. Leuk Lymphoma. 2025 Feb; 66 (2):270-278 Epub 2024 Oct 14
    View PubMed
  15. Shadman M, Salkar M, Srivastava B, Karve S, Emond B, Gogna P, Manceur AM, Lafeuille MH, Rava A, Sun H, Howarth A, Tomicki S, Agatep B, Jones B, Franceschini E, Saifan C, Bacchus S, Roeker L, Stephens DM. Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma. 2025 Jan; 66 (1):44-53 Epub 2024 Oct 01
    View PubMed
  16. Shah NN, Wang M, Roeker LE, Patel K, Woyach JA, Wierda WG, Ujjani CS, Eyre TA, Zinzani PL, Alencar AJ, Ghia P, Lamanna N, Hoffmann MS, Patel MR, Flinn I, Gerson JN, Ma S, Coombs CC, Cheah CY, Lech-Maranda E, Fakhri B, Kim WS, Barve MA, Cohen JB, Jurczak W, Munir T, Thompson MC, Tsai DE, Bao K, Cangemi NA, Kherani JF, Walgren RA, Han H, Ruppert AS, Brown JR. Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. Haematologica. 2025 Jan 1; 110 (1):92-102 Epub 2025 Jan 01
    View PubMed
  17. Roeker LE, Coombs CC, Shah NN, Jurczak W, Woyach JA, Cheah CY, Patel K, Maddocks K, Wang Y, Zinzani PL, Munir T, Koh Y, Thompson MC, Muehlenbein CE, Wang C, Sizelove R, Abhyankar S, Hasanabba S, Tsai DE, Eyre TA, Wang M. Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies. Acta Haematol. 2025; 148 (2):180-197 Epub 2024 June 05
    View PubMed
  18. Curtis KL, Corley EM, Gottesdiener LS, Hissong EM, Kaplan A, Roeker LE, Kodiyanplakkal RPL. Chronic Enterovirus Meningitis with Acute Hepatitis in a Patient with Chronic Lymphocytic Leukemia Treated with Venetoclax/Obinutuzumab: A Case Report. Case Rep Oncol. 2025 Jan-Dec; 18 (1):1089-1098 Epub 2025 June 14
    View PubMed
  19. Valtis YK, Nemirovsky D, Derkach A, Sharan S, Kabel C, Ortiz R, Thompson MC, Roeker LE, Geyer MB. Real-world incidence and prevention of tumor lysis syndrome in chronic lymphocytic leukemia treated with venetoclax. Blood Adv. 2024 Nov 26; 8 (22):5806-5813
    View PubMed
  20. Roeker LE, Woyach JA, Cheah CY, Coombs CC, Shah NN, Wierda WG, Patel MR, Lamanna N, Tsai DE, Nair B, Wang C, Zhao X, Liu D, Radtke D, Chapman S, Marella N, McNeely SC, Brown JR. Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. Blood. 2024 Sep 26; 144 (13):1374-1386
    View PubMed
  21. Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffmann MS, Coombs CC, Lamanna N, Ma S, Jagadeesh D, Munir T, Wang Y, Eyre TA, Rhodes JM, McKinney M, Lech-Maranda E, Tam CS, Jurczak W, Izutsu K, Alencar AJ, Patel MR, Seymour JF, Woyach JA, Thompson PA, Abada PB, Ho C, McNeely SC, Marella N, Nguyen B, Wang C, Ruppert AS, Nair B, Liu H, Tsai DE, Roeker LE, Ghia P. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. Lancet Haematol. 2024 Sep; 11 (9):e682-e692 Epub 2024 July 18
    View PubMed
  22. Samples L, Voutsinas J, Fakhri B, Khajavian S, Spurgeon S, Stephens D, Skarbnik A, Mato A, Broome C, Gopal A, Smith S, Lynch R, Rainey M, Kim MS, Barrett-Campbell O, Hemond E, Tsang M, Ermann D, Malakhov N, Rao D, Shakib-Azar M, Morrigan B, Chauhan A, Plate T, Gooley T, Ryan K, Lansigan F, Hill B, Pongas G, Parikh SA, Roeker L, Allan JN, Cheng R, Ujjani C, Shadman M. Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study. Blood Adv. 2024 May 14; 8(9):2085-2093.
    View PubMed
  23. Montoya S, Bourcier J, Noviski M, Lu H, Thompson MC, Chirino A, Jahn J, Sondhi AK, Gajewski S, Tan YSM, Yung S, Urban A, Wang E, Han C, Mi X, Kim WJ, Sievers Q, Auger P, Bousquet H, Brathaban N, Bravo B, Gessner M, Guiducci C, Iuliano JN, Kane T, Mukerji R, Reddy PJ, Powers J, Sanchez Garcia de Los Rios M, Ye J, Barrientos Risso C, Tsai D, Pardo G, Notti RQ, Pardo A, Affer M, Nawaratne V, Totiger TM, Pena-Velasquez C, Rhodes JM, Zelenetz AD, Alencar A, Roeker LE, Mehta S, Garippa R, Linley A, Soni RK, Skanland SS, Brown RJ, Mato AR, Hansen GM, Abdel-Wahab O, Taylor J. Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127. Science. 2024 Feb 2; 383 (6682):eadi5798 Epub 2024 Feb 02
    View PubMed
  24. Laracy JC, Yan J, Steiger SN, Tan CA, Cohen N, Robilotti EV, Fender J, Cohen S, Korde N, Lee-Teh M, Noy A, Oved JH, Roeker LE, Shah G, Babady NE, Kamboj M, Seo SK. Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients. Haematologica. 2023 Nov 1; 108 (11):3058-3067 Epub 2023 Nov 01
    View PubMed
  25. Roeker LE, DerSarkissian M, Ryan K, Chen Y, Duh MS, Wahlstrom SK, Hakre S, Yu L, Guo H, Mato AR. Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia. Blood Adv. 2023 Aug 22; 7 (16):4291-4301
    View PubMed
  26. Shadman M, Manzoor BS, Sail K, Tuncer HH, Allan JN, Ujjani C, Emechebe N, Kamalakar R, Coombs CC, Leslie L, Barr PM, Brown JR, Eyre TA, Rampotas A, Schuh A, Lamanna N, Skarbnik A, Roeker LE, Bannerji R, Eichhorst B, Fleury I, Davids MS, Alhasani H, Jiang D, Hill BT, Schuster SJ, Brander DM, Pivneva I, Burne R, Guerin A, Mato AR. Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study. Clin Lymphoma Myeloma Leuk. 2023 Jul; 23 (7):515-526 Epub 2023 Mar 24
    View PubMed
  27. Petrova-Drus K, Syed M, Yu W, Hutt K, Zlotnicki AM, Huang Y, Kamalska-Cyganik M, Maciag L, Wang M, Ma YG, Ho C, Moung C, Yao J, Nafa K, Baik J, Vanderbilt CM, Benhamida JK, Liu Y, Zhu M, Durham B, Ewalt MD, Salazar P, Rijo I, Baldi T, Mato A, Roeker LE, Roshal M, Dogan A, Arcila ME. Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Detailed Description of the Technical Performance, Clinical Utility, and Platform Comparison. J Mol Diagn. 2023 Jun; 25 (6):352-366 Epub 2023 Mar 23
    View PubMed
  28. Eyre TA, Hess LM, Sugihara T, He D, Khanal M, Pagel JM, Walgren RA, B Abada P, Konig H, Roeker LE, Mato A. Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study. Leuk Lymphoma. 2023 May; 64 (5):1005-1016 Epub 2023 Mar 29
    View PubMed
  29. Karr M, Roeker L. A History of Targeted Therapy Development and Progress in Novel-Novel Combinations for Chronic Lymphocytic Leukemia (CLL). Cancers (Basel). 2023 Feb 6; 15 (4) Epub 2023 Feb 06
    View PubMed
  30. Bantilan KS, Kay NE, Parikh SA, Rabe KG, Call TG, Leis JF, Ding W, Slager SL, Soumerai JD, Roeker LE, Mato A, Zelenetz AD. Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leuk Lymphoma. 2023 Feb; 64(2):300-311. Epub 2022 Dec 12.
    View PubMed
  31. Mato A, Tang B, Azmi S, Yang K, Han Y, Zhang X, Roeker L, Wallis N, Stern JC, Hedrick E, Huang J, Sharman JP. A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States. EJHaem. 2023 Feb; 4 (1):135-144 Epub 2023 Jan 23
    View PubMed
  32. Aronson JH, Skanland SS, Roeker LE, Thompson MC, Mato AR. Approach to a patient with "double refractory" chronic lymphocytic leukemia: "Double, double toil and trouble" (Shakespeare). Am J Hematol. 2022 Nov; 97 Suppl 2:S19-S25
    View PubMed
  33. Coombs CC, Pagel JM, Shah NN, Lamanna N, Munir T, Lech-Maranda E, Eyre TA, Woyach JA, Wierda WG, Cheah CY, Cohen JB, Roeker LE, Patel MR, Fakhri B, Barve MA, Tam CS, Lewis D, Gerson JN, Alencar A, Ujjani C, Flinn I, Sundaram S, Ma S, Jagadeesh D, Rhodes J, Taylor J, Abdel-Wahab O, Ghia P, Schuster SJ, Wang D, Nair B, Zhu E, Tsai DE, Davids MS, Brown JR, Jurczak W, Mato AR. CLL-120 Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase ½ BRUIN Study Clin Lymphoma Myeloma Leuk. 2022; (Suppl 2:S268-S269.).
  34. Ryan CE, Davids MS, Hermann R, Shahkarami M, Biondo J, Abhyankar S, Alhasani H, Sharman JP, Mato AR, Roeker LE. MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Future Oncol. 2022 Oct; 18 (33):3689-3699 Epub 2022 Sept 14
    View PubMed
  35. Roeker LE, Feldman TA, Soumerai JD, Falco V, Panton G, Dorsey C, Zelenetz AD, Falchi L, Park JH, Straus DJ, Pena Velasquez C, Lebowitz S, Fox Y, Battiato K, Laudati C, Thompson MC, McCarthy E, Kdiry S, Martignetti R, Turpuseema T, Purdom M, Paskalis D, Miskin HP, Sportelli P, Leslie LA, Mato AR. Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach. Clin Cancer Res. 2022 Sep 15; 28 (18):3958-3964
    View PubMed
  36. Mato AR, Roeker LE. Novel-agent combination therapies in chronic lymphocytic leukemia: the law of relative contributions. Haematologica 2022 Sep 1; 107 (9):2016-2017 Epub 2022 Sept 01
    View PubMed
  37. Thompson MC, Harrup RA, Coombs CC, Roeker LE, Pu JJ, Choi MY, Barr PM, Allan JN, Simkovic M, Leslie L, Rhodes J, Chong EA, Kamdar M, Skarbnik A, Lansigan F, McCall B, Saja K, Dyer MJS, Walter HS, Lefebure M, Thadani-Mulero M, Boyer M, Biondo J, Sail K, Manzoor BS, Furman R, Bantilan KS, Goy A, Feldman T, Labella D, Schuster SJ, Park J, Palomba L, Zelenetz A, Eyre TA, Kater AP, Seymour JF, Mato AR. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood Adv. 2022 Aug 9; 6 (15):4553-4557
    View PubMed
  38. Nocco S, Andriano TM, Bose A, Chilov M, Godwin K, Dranitsaris G, Wu S, Lacouture ME, Roeker LE, Mato AR, Markova A. Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2022 Jun; 174:103696 Epub 2022 May 06
    View PubMed
  39. Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, Durham BH, Penson A, Witkowski MT, Lu SX, Bourcier J, Hogg SJ, Erickson C, Cui D, Cho H, Singer M, Totiger TM, Chaudhry S, Geyer M, Alencar A, Linley AJ, Palomba ML, Coombs CC, Park JH, Zelenetz A, Roeker L, Rosendahl M, Tsai DE, Ebata K, Brandhuber B, Hyman DM, Aifantis I, Mato A, Taylor J, Abdel-Wahab O. Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. N Engl J Med. 2022 Feb 24; 386 (8):735-743
    View PubMed
  40. Mato AR, Davids MS, Sharman J, Roeker LE, Kay N, Kater AP, Rogers K, Thompson MC, Rhodes J, Goy A, Skarbnik A, Schuster SJ, Tam CS, Eyre TA, O'Brien S, Nabhan C, Lamanna N, Sun C, Shadman M, Pagel JM, Ujjani C, Brander D, Coombs CC, Jain N, Cheah CY, Brown JR, Seymour JF, Woyach JA. Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare). Clin Cancer Res. 2022 Feb 15; 28(4):603-608.
    View PubMed
  41. Roeker LE, Thompson M, Mato AR. Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy. Drugs. 2022 Feb; 82 (2):133-143 Epub 2021 Dec 21
    View PubMed
  42. Jensen JL, Mato AR, Pena C, Roeker LE, Coombs CC. The potential of pirtobrutinib in multiple B-cell malignancies. Ther Adv Hematol. 2022; 13:20406207221101697 Epub 2022 June 16
    View PubMed
  43. Soumerai JD, Mato AR, Dogan A, Seshan VE, Joffe E, Flaherty K, Carter J, Hochberg E, Barnes JA, Hamilton AM, Abramson JS, Batlevi CL, Matasar MJ, Noy A, Owens CN, Palomba ML, Kumar A, Takvorian T, Ni A, Choma M, Friedman C, Chadha P, Simkins E, Ruiters J, Sechio S, Portman D, Ramos L, Nolet N, Mahajan N, Martignetti R, Mi J, Scorsune K, Lynch J, McGree B, Hughes S, Grieve C, Roeker LE, Thompson M, Johnson PC, Roshal M, Huang J, Biondo J, Wu Q, Jacob A, Abdel-Wahab O, Zelenetz AD. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2021 Dec; 8 (12):e879-e890
    View PubMed
  44. Chung DJ, Shah GL, Devlin SM, Ramanathan LV, Doddi S, Pessin MS, Hoover E, Marcello LT, Young JC, Boutemine SR, Serrano E, Sharan S, Momotaj S, Margetich L, Bravo CD, Papanicolaou GA, Kamboj M, Mato AR, Roeker LE, Hultcrantz M, Mailankody S, Lesokhin AM, Vardhana SA, Knorr DA. Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies. Blood Cancer Discov 2021 Nov; 2 (6):568-576 Epub 2021 Sept 13
    View PubMed
  45. Stahl M, Narendra V, Jee J, Derkach A, Maloy M, Geyer MB, Mato AR, Roeker LE, Tallman MS, Shah GL, Daniyan A, Goldberg AD. Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality. Leuk Lymphoma. 2021 Aug; 62 (8):1940-1948 Epub 2021 June 28
    View PubMed
  46. Lahoud OB, Devlin SM, Maloy MA, Roeker LE, Dahi PB, Ponce DM, Gyurkocza B, Koehne G, Young JW, Castro-Malaspina HR, Barker JN, Papadopoulos EB, Jakubowski AA, Zelenetz AD, Mato AR, Giralt SA, Perales MA, Sauter CS. Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation. Blood Adv. 2021 Jul 27; 5 (14):2879-2889
    View PubMed
  47. Roeker LE, Thompson MC, Mato AR. Searching for a home: phosphoinositide 3-kinase inhibitors for chronic lymphocytic leukaemia in modern clinical practice. Br J Haematol 2021 Jul; 194 (1):9-10 Epub 2021 June 15
    View PubMed
  48. Mato AR, Ghosh N, Schuster SJ, Lamanna N, Pagel JM, Flinn IW, Barrientos JC, Rai KR, Reeves JA, Cheson BD, Barr PM, Kambhampati S, Lansigan F, Pu JJ, Skarbnik AP, Roeker L, Fonseca GA, Sitlinger A, Hamadeh IS, Dorsey C, LaRatta N, Weissbrot H, Luning Prak ET, Tsao P, Paskalis D, Sportelli P, Miskin HP, Weiss MS, Svoboda J, Brander DM. Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kdelta inhibitor therapy. Blood. 2021 May 20; 137 (20):2817-2826
    View PubMed
  49. Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 Mar 6; 397 (10277):892-901
    View PubMed
  50. Roeker LE, Mato AR. Approaches for relapsed CLL after chemotherapy-free frontline regimens. Hematology Am Soc Hematol Educ Program. 2020 Dec 4; 2020 (1):10-17
    View PubMed
  51. Roeker LE, Knorr DA, Pessin MS, Ramanathan LV, Thompson MC, Leslie LA, Zelenetz AD, Mato AR. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia. 2020 Nov; 34 (11):3047-3049 Epub 2020 Aug 27
    View PubMed
  52. Cuneo A, Mato AR, Rigolin GM, Piciocchi A, Gentile M, Laurenti L, Allan JN, Pagel JM, Brander DM, Hill BT, Winter A, Lamanna N, Tam CS, Jacobs R, Lansigan F, Barr PM, Shadman M, Skarbnik AP, Pu JJ, Sehgal AR, Schuster SJ, Shah NN, Ujjani CS, Roeker L, Orlandi EM, Billio A, Trentin L, Spacek M, Marchetti M, Tedeschi A, Ilariucci F, Gaidano G, Doubek M, Farina L, Molica S, Di Raimondo F, Coscia M, Mauro FR, de la Serna J, Medina Perez A, Ferrarini I, Cimino G, Cavallari M, Cucci R, Vignetti M, Foa R, Ghia P, GIMEMA, European Research Initiative (ERIC) on CLL, US study group. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. Cancer Med. 2020 Nov; 9 (22):8468-8479 Epub 2020 Sept 24
    View PubMed
  53. Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, Patel K, Osterborg A, Wojenski D, Kamdar M, Huntington SF, Davids MS, Brown JR, Antic D, Jacobs R, Ahn IE, Pu J, Isaac KM, Barr PM, Ujjani CS, Geyer MB, Berman E, Zelenetz AD, Malakhov N, Furman RR, Koropsak M, Bailey N, Hanson L, Perini GF, Ma S, Ryan CE, Wiestner A, Portell CA, Shadman M, Chong EA, Brander DM, Sundaram S, Seddon AN, Seymour E, Patel M, Martinez-Calle N, Munir T, Walewska R, Broom A, Walter H, El-Sharkawi D, Parry H, Wilson MR, Patten PEM, Hernandez-Rivas JA, Miras F, Fernandez Escalada N, Ghione P, Nabhan C, Lebowitz S, Bhavsar E, Lopez-Jimenez J, Naya D, Garcia-Marco JA, Skanland SS, Cordoba R, Eyre TA. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020 Sep 3; 136 (10):1134-1143
    View PubMed
  54. Roeker LE, Dreger P, Brown JR, Lahoud OB, Eyre TA, Brander DM, Skarbnik A, Coombs CC, Kim HT, Davids M, Manchini ST, George G, Shah N, Voorhees TJ, Orchard KH, Walter HS, Arumainathan AK, Sitlinger A, Park JH, Geyer MB, Zelenetz AD, Sauter CS, Giralt SA, Perales MA, Mato AR. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020 Aug 25; 4 (16):3977-3989
    View PubMed
  55. Mato AR, Roeker LE, Jacobs R, Hill BT, Lamanna N, Brander D, Shadman M, Ujjani CS, Yazdy MS, Perini GF, Pinilla-Ibarz JA, Barrientos J, Skarbnik AP, Torka P, Pu JJ, Pagel JM, Gohil S, Fakhri B, Choi M, Coombs CC, Rhodes J, Barr PM, Portell CA, Parry H, Garcia CA, Whitaker KJ, Winter AM, Sitlinger A, Khajavian S, Grajales-Cruz AF, Isaac KM, Shah P, Akhtar OS, Pocock R, Lam K, Voorhees TJ, Schuster SJ, Rodgers TD, Fox CP, Martinez-Calle N, Munir T, Bhavsar EB, Bailey N, Lee JC, Weissbrot HB, Nabhan C, Goodfriend JM, King AC, Zelenetz AD, Dorsey C, Bigelow K, Cheson BD, Allan JN, Eyre TA. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. Clin Cancer Res 2020 Jul 15; 26 (14):3589-3596 Epub 2020 Mar 20
    View PubMed
  56. Chong EA, Roeker LE, Shadman M, Davids MS, Schuster SJ, Mato AR. BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte). Clin Cancer Res. 2020 Jul 15; 26 (14):3514-3516 Epub 2020 Apr 28
    View PubMed
  57. Eyre TA, Roeker LE, Fox CP, Gohill SH, Walewska R, Walter HS, Forconi F, Broom A, Arumainathan A, Brander DM, Allan JN, Schuster SJ, Hill BT, Lansigan F, Cheson BD, Lamanna N, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Pearson L, Pagel JM, Jacobs R, Mato AR. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. Br J Haematol. 2020 Mar; 188 (6):918-923 Epub 2019 Nov 04
    View PubMed
  58. Lewis C, Kim HT, Roeker LE, Cutler C, Koreth J, Nikiforow S, Armand P, Gootpu M, Romee R, Glotzbecker B, Nageshwar P, Antin JH, Alyea EP, Richardson P, Soiffer RJ, Ho VT. Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 Mar; 26 (3):529-539 Epub 2019 Oct 31
    View PubMed
  59. Ujjani C, Mato A, Hill BT, Allan JN, Lansigan F, Jacobs R, Skarbnik A, Tuncer H, Pagel J, Brander D, Cheson B, Barr P, Roeker LE, Pu J, Shah NN, Goy A, Schuster SJ, Lamanna N, Sehgal A, Tam CS, Shadman M. The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy. Blood Lymphat Cancer. 2020; 10:1-5 Epub 2020 Aug 24
    View PubMed
  60. Roeker LE, Sarraf Yazdy M, Rhodes J, Goodfriend J, Narkhede M, Carver J, Mato A. Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia. JAMA Netw Open. 2019 Dec 2; 2 (12):e1916326 Epub 2019 Dec 02
    View PubMed
  61. Roeker LE, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Clin Cancer Res. 2019 Jul 15; 25 (14):4264-4270 Epub 2019 Apr 19
    View PubMed
  62. Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Yazdy MS, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP. A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. Blood Adv. 2019 May 28; 3 (10):1568-1573
    View PubMed
  63. Roeker LE, Kim HT, Glotzbecker B, Nageshwar P, Nikiforow S, Koreth J, Armand P, Cutler C, Alyea EP, Antin JH, Richardson PG, Soiffer RJ, Ho VT. Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 Jan; 25 (1):137-144 Epub 2018 Aug 03
    View PubMed
  64. Ravi P, Kumar SK, Roeker L, Gonsalves W, Buadi F, Lacy MQ, Go RS, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer J. 2018 Nov 15; 8(12):116.
    View PubMed
  65. Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. Am J Hematol. 2018 Nov; 93 (11):1394-1401 Epub 2018 Sept 26
    View PubMed
  66. Bange E, Timlin C, Kabel C, Svoboda J, Roeker L, Mato AR. Evidence for and Against Green Tea and Turmeric in the Management of Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2018 Oct; 18 (10):e421-e426 Epub 2018 June 27
    View PubMed
  67. Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018 Sep; 103(9):1511-1517. Epub 2018 Jun 07.
    View PubMed
  68. Banerjee D, Roeker LE, Grogan M, Swiecicki P, Poterucha J, Heimbach J, Zeldenrust S, Gertz M, Edwards B, Daly R, Klarich KW, Dispenzieri A. Outcomes of Patients With Familial Transthyretin Amyloidosis After Liver Transplantation. Prog Transplant. 2017 Sep; 27(3):246-250. Epub 2017 Jul 04.
    View PubMed
  69. Grogan M, Gertz M, McCurdy A, Roeker L, Kyle R, Kushwaha S, Daly R, Dearani J, Rodeheffer R, Frantz R, Lacy M, Hayman S, McGregor C, Edwards B, Dispenzieri A. Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. World J Transplant. 2016 Jun 24; 6(2):380-8.
    View PubMed
  70. Roeker LE, Wolanskyj AP. Imatinib-associated melanosis of the palate. Am J Hematol. 2014 May; 89 (5):564 Epub 2014 Mar 03
    View PubMed
  71. Handlogten KS, Molitor RJ, Roeker LE, Narla NP, Bachman MJ, Quayson S, Owusu-Afriyie O, Adjei E, Ankobea F, Clayton A, Roberts L, MacLaughlin K, Ansong D. Cervical cancer screening in Ghana, west Africa: prevalence of abnormal cytology and challenges for expanding screening. Int J Gynecol Pathol. 2014 Mar; 33(2):197-202.
    View PubMed
  72. Lim MY, Stephens EK, Novotny P, Price K, Salayi M, Roeker L, Peethambaram P, Jatoi A. Self-perceptions of age among 292 chemotherapy-treated cancer patients: Exploring associations with symptoms and survival. J Geriatr Oncol. 2013 Jul; 4(3):249-54.
    View PubMed
  73. Roeker LE, Larson DR, Kyle RA, Kumar S, Dispenzieri A, Rajkumar SV. Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17?315 patients. Leukemia. 2013 Jun; 27(6):1391-3. Epub 2013 Feb 05.
    View PubMed
  74. Roeker LE, Gupta V, Gonsalves WI, Wolanskyj AP, Gangat N. Cyclic bicytopenia in a patient with shapiro syndrome. Case Rep Hematol. 2013; 2013:231713 Epub 2013 Sept 25
    View PubMed
  75. Vaa BE, Wolanskyj AP, Roeker L, Pardanani A, Lasho TL, Finke CM, Tefferi A. Pruritus in primary myelofibrosis: clinical and laboratory correlates. Am J Hematol. 2012 Feb; 87(2):136-8. Epub 2011 Nov 12.
    View PubMed